Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

GLP-1 receptor agonists, best known for weight loss and diabetes, may also shield patients with systemic sclerosis (SSc) from serious lung complications. A retrospective study found SSc patients on GLP-1s had significantly lower rates of interstitial lung disease, pulmonary hypertension, and cardiovascular events compared to non-users. Researchers call the findings hypothesis-generating and a potential new direction for SSc management.
GLP-1 receptor agonists — the blockbuster drug class behind medications like semaglutide — may offer a surprising benefit for patients with systemic sclerosis (SSc) and obesity: protection against life-threatening pulmonary complications. Data presented at ACR Convergence 2026 showed that SSc patients who used GLP-1s had dramatically lower 10-year rates of interstitial lung disease (ILD) and pulmonary hypertension compared to those who didn't.
The retrospective cohort study, drawn from the TriNetX database, analyzed 1,578 matched pairs of adults with SSc and obesity. Researchers isolated the GLP-1 effect by excluding the confounding influence of diabetes. Beyond lung outcomes, GLP-1 users also showed lower risks for major cardiovascular events, all-cause mortality, acute kidney injury, and chronic steroid use.
By the Numbers:
Why it matters: Current SSc therapies are effective but incomplete, and pulmonary complications are on the rise in this population. While researchers caution these findings are hypothesis-generating rather than practice-changing, they open an exciting door for GLP-1s as a potential multi-system treatment in SSc.